Collegium Pharmaceutical, Inc COLL
We take great care to ensure that the data presented and summarized in this overview for COLLEGIUM PHARMACEUTICAL, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding COLL
View all-
Black Rock Inc. New York, NY5.87MShares$194 Million0.01% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.63MShares$87.3 Million1.65% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.59MShares$85.7 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.33MShares$77.2 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY1.83MShares$60.8 Million2.43% of portfolio
-
Invesco Ltd. Atlanta, GA1.63MShares$54.1 Million0.01% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.55MShares$51.5 Million0.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.42MShares$47 Million0.09% of portfolio
-
State Street Corp Boston, MA1.32MShares$43.7 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.02MShares$33.8 Million0.01% of portfolio
Latest Institutional Activity in COLL
Top Purchases
Top Sells
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Insider Transactions at COLL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 28
2024
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,710
-13.09%
|
$670,140
$34.21 P/Share
|
|
May 24
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
56,807
-34.91%
|
$1,874,631
$33.98 P/Share
|
|
May 24
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,791
+12.76%
|
$570,984
$24.03 P/Share
|
|
May 23
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
51,209
-26.93%
|
$1,689,897
$33.82 P/Share
|
|
May 23
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,209
+21.22%
|
$1,229,016
$24.03 P/Share
|
|
May 16
2024
|
Garen G Bohlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
|
May 16
2024
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+14.46%
|
-
|
|
May 16
2024
|
Rita J. Balice Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+14.2%
|
-
|
|
May 16
2024
|
John A. Fallon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.3%
|
-
|
|
May 16
2024
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
|
May 16
2024
|
Neil F. Mc Farlane Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+13.48%
|
-
|
|
May 16
2024
|
Gwen A Melincoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
|
May 16
2024
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+9.23%
|
-
|
|
May 14
2024
|
Garen G Bohlin Director |
SELL
Open market or private sale
|
Direct |
28,985
-39.3%
|
$927,520
$32.3 P/Share
|
|
May 14
2024
|
Garen G Bohlin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
28,985
+28.21%
|
$144,925
$5.73 P/Share
|
|
Feb 29
2024
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
995
-1.54%
|
$35,820
$36.76 P/Share
|
|
Feb 26
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.37%
|
$360,000
$36.77 P/Share
|
|
Feb 12
2024
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,199
-2.39%
|
$105,567
$33.7 P/Share
|
|
Feb 12
2024
|
Thomas B Smith EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,423
+19.62%
|
-
|
|
Feb 12
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,690
-8.66%
|
$979,770
$33.7 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 611K shares |
|---|---|
| Exercise of conversion of derivative security | 203K shares |
| Payment of exercise price or tax liability | 220K shares |
|---|---|
| Open market or private sale | 339K shares |